Vorapaxar in the Secondary Prevention of Atherothrombotic Events
Vorapaxar in the Secondary Prevention of Atherothrombotic Events
About this item
Full title
Author / Creator
TRA 2P–TIMI 50 Steering Committee and Investigators , Morrow, David A , Braunwald, Eugene , Bonaca, Marc P , Ameriso, Sebastian F , Dalby, Anthony J , Fish, Mary Polly , Fox, Keith A.A , Lipka, Leslie J , Liu, Xuan , Nicolau, José Carlos , Ophuis, A.J. Oude , Paolasso, Ernesto , Scirica, Benjamin M , Spinar, Jindrich , Theroux, Pierre , Wiviott, Stephen D , Strony, John and Murphy, Sabina A
Publisher
Waltham, MA: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
Waltham, MA: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Patients with atherosclerotic vascular disease were randomly assigned to receive the thrombin antagonist vorapaxar or placebo. Vorapaxar reduced the rate of subsequent cardiovascular death, myocardial infarction, or stroke but increased the rate of moderate or severe bleeding.
Platelets play a central role in atherothrombosis and are an importan...
Alternative Titles
Full title
Vorapaxar in the Secondary Prevention of Atherothrombotic Events
Authors, Artists and Contributors
Author / Creator
Morrow, David A
Braunwald, Eugene
Bonaca, Marc P
Ameriso, Sebastian F
Dalby, Anthony J
Fish, Mary Polly
Fox, Keith A.A
Lipka, Leslie J
Liu, Xuan
Nicolau, José Carlos
Ophuis, A.J. Oude
Paolasso, Ernesto
Scirica, Benjamin M
Spinar, Jindrich
Theroux, Pierre
Wiviott, Stephen D
Strony, John
Murphy, Sabina A
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_hal_primary_oai_HAL_hal_00793696v1
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_hal_00793696v1
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1200933
